Alkermes plc Ordinary Shares (NASDAQ:ALKS)

Home >> Stock >> Alkermes plc Ordinary Shares >> Metrics

Alkermes plc, formed by the merger of Waltham, MA-based Alkermes, Inc. and Elan Drug Technologies (EDT), is a fully integrated global biopharmaceutical company that utilizes proprietary technologies to research, develop and commercialize, both with partners and on its own pharmaceutical products in major therapeutic areas. Alkermes holds a diversified product portfolio and a promising pipeline of candidates targeting major central nervous system (CNS) disorders including schizophrenia, depression, addiction and multiple sclerosis. Alkermes derives revenues on net sales of its proprietary products: Vivitrol & Aristada, and manufacturing and/or royalty revenues on net sales of products commercialized by the company's partners. These include Risperdal Consta, Invega Sustenna/Xeplion, Invega Trinza/Trevicta, Ampyra/Fampyra and Bydureon. Interesting late-stage candidate in the company's pipeline include nemvaleukin alfa developed for treating advanced solid tumors. Its proprietary drugs are Vivitrol & Aristada....

+See More
See More

Blog+More

U.S. federalism and domestic institutional arrangements

Olivia London

2023-12-10 09:23:00 Sunday ET

U.S. federalism and domestic institutional arrangements

U.S. federalism and domestic institutional arrangements A given country is federal when both of its national and sub-national governments exercise separa

+See More

Corporate investment management

Charlene Vos

2022-04-15 10:32:00 Friday ET

Corporate investment management

Corporate investment management  This review of corporate investment literature focuses on some recent empirical studies of M&A, capital investm

+See More

President Trump introduces $50 billion tariffs on Chinese products and new limits on Chinese high-tech investments in America.

Apple Boston

2018-05-25 07:30:00 Friday ET

President Trump introduces $50 billion tariffs on Chinese products and new limits on Chinese high-tech investments in America.

President Trump introduces $50 billion tariffs on Chinese products and new limits on Chinese high-tech investments in America. This new round of tariffs

+See More

AT&T wins court approval to take over Time Warner with a trademark $85 billion bid despite the Trump prior dissent due to antitrust concerns.

Chanel Holden

2018-06-07 10:36:00 Thursday ET

AT&T wins court approval to take over Time Warner with a trademark $85 billion bid despite the Trump prior dissent due to antitrust concerns.

AT&T wins court approval to take over Time Warner with a trademark $85 billion bid despite the Trump administration prior dissent due to antitrust conce

+See More

Trump's presidential election victory caused an unpredictable *black swan* in almost every non-U.S. stock market in the world.

Fiona Sydney

2016-11-09 00:00:00 Wednesday ET

Trump's presidential election victory caused an unpredictable *black swan* in almost every non-U.S. stock market in the world.

Universally dismissed as a vanity presidential candidate when he entered a field crowded with Republican talent, the former Democrat and former Independent

+See More

President Trump withdraws America from the Iran nuclear agreement and revives economic sanctions on Iran for better negotiations.

Chanel Holden

2018-05-06 07:30:00 Sunday ET

President Trump withdraws America from the Iran nuclear agreement and revives economic sanctions on Iran for better negotiations.

President Trump withdraws America from the Iran nuclear agreement and revives economic sanctions on Iran for better negotiations as western allies Britain,

+See More